SG11202106283SA - Methods for improving exercise tolerance in myalgic encephalomyelitis patients - Google Patents
Methods for improving exercise tolerance in myalgic encephalomyelitis patientsInfo
- Publication number
- SG11202106283SA SG11202106283SA SG11202106283SA SG11202106283SA SG11202106283SA SG 11202106283S A SG11202106283S A SG 11202106283SA SG 11202106283S A SG11202106283S A SG 11202106283SA SG 11202106283S A SG11202106283S A SG 11202106283SA SG 11202106283S A SG11202106283S A SG 11202106283SA
- Authority
- SG
- Singapore
- Prior art keywords
- patients
- methods
- exercise tolerance
- improving exercise
- myalgic encephalomyelitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778935P | 2018-12-13 | 2018-12-13 | |
| PCT/US2019/063048 WO2020123136A1 (en) | 2018-12-13 | 2019-11-25 | Methods for improving exercise tolerance in myalgic encephalomyelitis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106283SA true SG11202106283SA (en) | 2021-07-29 |
Family
ID=69005827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106283SA SG11202106283SA (en) | 2018-12-13 | 2019-11-25 | Methods for improving exercise tolerance in myalgic encephalomyelitis patients |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11813281B2 (en) |
| EP (1) | EP3893893A1 (en) |
| JP (1) | JP7475702B2 (en) |
| KR (1) | KR20210104782A (en) |
| CN (1) | CN113194963A (en) |
| AR (1) | AR117696A1 (en) |
| AU (1) | AU2019398016A1 (en) |
| BR (1) | BR112021011331A2 (en) |
| CA (1) | CA3123379A1 (en) |
| MX (1) | MX2021007026A (en) |
| SG (1) | SG11202106283SA (en) |
| WO (1) | WO2020123136A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220387472A1 (en) * | 2020-09-21 | 2022-12-08 | Aim Immunotech Inc. | Compositions and methods for treating cancer |
| EP4334451A1 (en) * | 2021-05-05 | 2024-03-13 | AIM ImmunoTech Inc. | Methods and compositions for treating neuroinflammation |
| NL2032813A (en) * | 2021-08-20 | 2023-02-27 | Aim Immunotech Inc | Compositions and methods for treating post-covid conditions of fatigue |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4024222A (en) | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
| ATE103493T1 (en) * | 1988-07-07 | 1994-04-15 | Hem Pharma Corp | DIAGNOSIS AND TREATMENT OF CHRONIC FATIGUE. |
| US5258369A (en) | 1988-08-29 | 1993-11-02 | Hem Pharmaceuticals Corporation | Treatment of chronic cerebral dysfunction by dsRNA methodology |
| CA2541090C (en) * | 2003-10-03 | 2013-04-16 | Veijlen N.V. | Use of indole acetic acid or derivatives thereof to increase igf-1 serum levels |
| WO2010042229A2 (en) | 2008-10-10 | 2010-04-15 | Hemispherx Biopharma, Inc. | Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3) |
| US8722874B2 (en) | 2008-10-23 | 2014-05-13 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| US20100160413A1 (en) | 2008-10-23 | 2010-06-24 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| US20120004290A1 (en) * | 2009-03-13 | 2012-01-05 | David Strayer | Treating chronic fatigue syndrome and prolonged qt interval |
| US8569255B2 (en) * | 2011-02-02 | 2013-10-29 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Post-exposure therapy of influenza A infections |
| AR093423A1 (en) | 2013-07-19 | 2015-06-03 | Hemispherx Biopharm Inc | METHOD OF DIAGNOSIS AND STABILIZATION OF CFS / ME SYMPTOMS IN A PATIENT |
-
2019
- 2019-11-25 JP JP2021534315A patent/JP7475702B2/en active Active
- 2019-11-25 CA CA3123379A patent/CA3123379A1/en active Pending
- 2019-11-25 US US17/413,387 patent/US11813281B2/en active Active
- 2019-11-25 WO PCT/US2019/063048 patent/WO2020123136A1/en unknown
- 2019-11-25 EP EP19827888.9A patent/EP3893893A1/en active Pending
- 2019-11-25 KR KR1020217021913A patent/KR20210104782A/en unknown
- 2019-11-25 BR BR112021011331-2A patent/BR112021011331A2/en unknown
- 2019-11-25 AU AU2019398016A patent/AU2019398016A1/en active Pending
- 2019-11-25 CN CN201980083124.1A patent/CN113194963A/en active Pending
- 2019-11-25 MX MX2021007026A patent/MX2021007026A/en unknown
- 2019-11-25 SG SG11202106283SA patent/SG11202106283SA/en unknown
- 2019-12-13 AR ARP190103668A patent/AR117696A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011331A2 (en) | 2021-08-31 |
| AR117696A1 (en) | 2021-08-25 |
| JP2022513905A (en) | 2022-02-09 |
| AU2019398016A1 (en) | 2021-07-22 |
| US20220062321A1 (en) | 2022-03-03 |
| WO2020123136A1 (en) | 2020-06-18 |
| JP7475702B2 (en) | 2024-04-30 |
| US11813281B2 (en) | 2023-11-14 |
| KR20210104782A (en) | 2021-08-25 |
| EP3893893A1 (en) | 2021-10-20 |
| MX2021007026A (en) | 2021-10-22 |
| CN113194963A (en) | 2021-07-30 |
| CA3123379A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3676095C0 (en) | Methods and apparatus for three-dimensional fabrication by tomographic back projections | |
| EP3293736C0 (en) | Tissue characterization based on machine learning in medical imaging | |
| SG11202106283SA (en) | Methods for improving exercise tolerance in myalgic encephalomyelitis patients | |
| IL282923A (en) | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers | |
| PT3518783T (en) | Apparatus and methods for tissue reduction | |
| IL262121A (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| HK1252860A1 (en) | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias | |
| GB2567294B (en) | Noise removal in magnetometer for medical use | |
| GB201802795D0 (en) | Patient assessment method | |
| EP4054597A4 (en) | Blood plasma fractions for use in muscle regeneration | |
| IL273470A (en) | Semaglutide in medical therapy | |
| EP3151932A4 (en) | Exercise device for blood circulation and metabolism in the knee | |
| GB201807410D0 (en) | Diagnostic method and therapy | |
| GB201503967D0 (en) | Biocompatible implants for use in tendon therapy | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| GB201507054D0 (en) | Patient positioning training apparatus | |
| ZA201405887B (en) | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine | |
| EP3471682C0 (en) | Device for massaging muscles in an oral cavity | |
| GB201600637D0 (en) | Therapeutic treatment methods and apparatus for use therein | |
| GB201806258D0 (en) | Improvements in or relating to apparatus for cooking | |
| IL286029A (en) | Potassium-binding agents for use in hemodialysis patients | |
| GB202020736D0 (en) | Methods for improving mitophagy in subjects | |
| GB201707861D0 (en) | Methods for improving mitophagy in subjects | |
| GB201707863D0 (en) | Methods for improving mitophagy in subjects | |
| GB2584924B (en) | Exercise device for use while seated |